Lymphoma treatment quality varies widely

We might know that certain hospitals, doctors, clinics, have tremendous reputations for treating lymphoma. We might assume though that whatever they know can somehow be accessed by our local oncologist. In other words, it shouldn't matter too, too much where you get your treatment, right? We hope?

Not so, according to Dr. Fausto R. Loberiza of the University of Nebraska Medical Center in Omaha, and the study he and his colleagues published in the online Journal of Clinical Oncology in mid-September 2009. Looking at over 2300 lymphoma patients in Nebraska and other midwestern states in the years between 1982 and 2006, they found the following:

Low- to intermediate-risk lymphoma patients living in rural areas fared worse if they got care at a community-based center, rather than a university-based treatment provider.

As for high-risk lymphoma, urban residents treated at an urban, university-based center survived longer than rural residents, as well as longer than urban residents cared for by community-based providers.

Survival for all urban patients and rural patients cared for at university centers was similar, but rural community-treated patients with low- to intermediate-risk disease were 37 percent more likely than urban university-treated patients to die within five years, and 26 percent more likely to die than their rural peers who got university-based care.

And for high-risk lymphoma patients, risk of death within five years was higher for all rural patients and community-treated urban patients than it was for urban university-treated patients.

Read more from Reuters' coverage here

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap